Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis : interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up
Papp, Kim A (K Papp Clinical Research and Probity Medical Research)
Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Ohtsuki, M. (Jichi Medical University)
Beissert, Stefan (Department of Dermatology. University Hospital Carl Gustav Carus. TU Dresden)
Zeng, J. (AbbVie Inc.)
Rubant, S. (AbbVie Inc.)
Sinvhal, R. (AbbVie Inc.)
Zhao, Y. (AbbVie Inc.)
Soliman, A.M. (AbbVie Inc.)
Alperovich, G. (AbbVie Inc.)
Leonardi, C. (Central Dermatology. Richmond Heights)

Data:	2021
Resum:	Background: Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long-term evaluation to assess the durability of their efficacy and safety profiles over time. Objectives: To evaluate the long-term efficacy and safety of risankizumab (RZB) for the treatment of psoriasis. Methods: LIMMitless is an ongoing, phase III, open-label extension study evaluating the long-term efficacy and safety of RZB in adults with moderate-to-severe plaque psoriasis following multiple phase II/III studies. This analysis assessed efficacy through 172 weeks of continuous RZB treatment by examining the proportion of patients achieving ≥ 90% or 100% improvement in Psoriasis Area and Severity Index (PASI 90 and PASI 100), static Physician's Global Assessment of clear or almost clear (sPGA 0/1) and Dermatology Life Quality Index of no effect on quality of life (DLQI 0/1). Safety was assessed by recording adverse events (AEs) through the data cutoff date. The study is registered at ClinicalTrials. gov (identifier: NCT03047395). Results: Of 955 patients randomized to RZB 150 mg in the base studies, 897 patients continued into LIMMitless; 799 patients were still receiving treatment in LIMMitless at the time of data cutoff for this analysis. After 172 weeks of continuous RZB treatment, 85·5% of patients achieved PASI 90, 54·4% achieved PASI 100, 85·2% achieved sPGA 0/1, and 78·4% achieved DLQI 0/1 using modified nonresponder imputation. Rates of AEs leading to discontinuation and AEs of safety interest were low with long-term treatment and comparable with those identified in the base studies. Conclusions: Overall, long-term continuous RZB was well tolerated and showed high and durable efficacy over 172 weeks.
Nota:	AbbVie Inc.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adult ; Antibodies, Monoclonal ; Double-Blind Method ; Follow-Up Studies ; Humans ; Psoriasis ; Quality of Life ; Severity of Illness Index ; Treatment Outcome
Publicat a:	British journal of dermatology, Vol. 185 Núm. 6 (december 2021) , p. 1135-1145, ISSN 1365-2133

DOI: 10.1111/bjd.20595
PMID: 34157132

11 p, 1.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats